Clinical Trial Update: Neoadjuvant Adebrelimab and Chemotherapy in High-rish ER+/HER2- BC [Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 2 neoadjuvant study of adebrelimab plus chemotherapy for high-risk ER+/HER2- breast cancer, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Adebrelimab (adebrelimab)

Snippet

Sponsor: Shanghai Jiao Tong University School of Medicine | Conditions: Breast Cancer | Phase 2 | Status: RECRUITING